Tata Group to launch India’s first CRISPR Covid-19 test, powered by CSIR-IGIB
Mumbai, September 19, 2020: The Tata CRISPR test, powered by CSIR-IGIB FELUDA, received regulatory approvals today from the Drug Controller General of India (DCGI) for commercial launch, as per ICMR guidelines, meeting high quality benchmarks with 96% sensitivity and 98% specificity for detecting the novel coronavirus. This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus.
The Tata CRISPR test is the world’s first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the virus causing Covid-19. This marks a significant achievement for the Indian scientific community, moving from R&D to a high-accuracy, scalable and reliable test in less than 100 days. The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests, with quicker turnaround time, less expensive equipment, and better ease of use. Moreover, CRISPR is a futuristic technology that can also be configured for detection of multiple other pathogens in the future.
The effort is the result of a fruitful collaboration between the scientific community and industry. The Tata Group has worked closely with CSIR-IGIB and ICMR to create a high-quality test that will help the nation ramp up Covid-19 testing quickly and economically, with a ‘Made in India’ product that is safe, reliable, affordable, and accessible.
Commenting on the development, Girish Krishnamurthy, CEO, TATA Medical and Diagnostics Ltd, said, “The approval for the Tata CRISPR test for COVID-19 will give a boost to the country’s efforts in fighting the global pandemic. The commercialization of the Tata CRISPR test reflects the tremendous R&D talent in the country, which can collaborate to transform India’s contributions to the global healthcare and scientific research world.”
Dr Shekhar C Mande, DG-CSIR complimented the CSIR-IGIB team of scientists and students, TATA Sons and DCGI for the exemplary work and collaboration carried out during the current pandemic leading to the approval of the novel diagnostic kit and paving the path for further innovations towards making India self-reliant.
Dr Anurag Agrawal, Director CSIR-IGIB expressed delight that work started by CSIR under the sickle cell mission for genome diagnostics and therapeutics led to new knowledge that could be harnessed to quickly develop new diagnostic test for SARS-CoV-2. He emphasized that this shows the interconnectedness of scientific knowledge and technology and the innovation of the young research team led by Dr Debojyoti Chakraborty and Dr Souvik Maiti.
About the Tata Group
Founded by Jamsetji Tata in 1868, the Tata group is a global enterprise, headquartered in India, comprising 30 companies across 10 verticals. The group operates in more than 100 countries across six continents, with a mission ‘To improve the quality of life of the communities we serve globally, through long-term stakeholder value creation based on Leadership with Trust’.
Tata Sons is the principal investment holding company and promoter of Tata companies. Sixty-six percent of the equity share capital of Tata Sons is held by philanthropic trusts, which support education, health, livelihood generation and art and culture. In 2017-18, the revenue of Tata companies, taken together, was $110.7 billion. These companies collectively employ over 700,000 people. Each Tata company or enterprise operates independently under the guidance and supervision of its own board of directors. There are 28 publicly-listed Tata enterprises with a combined market capitalisation of about $145.3 billion (as on March 31, 2018). Companies include Tata Consultancy Services, Tata Motors, Tata Steel, Tata Chemicals, Tata Consumer Products, Titan, Tata Capital, Tata Power, Tata Advanced Systems, Indian Hotels and Tata Communications.
